Keywords: AstraZeneca, Pozen, Targacept, Vimovo, FDA approval, TC-5619, ADHA, Alzheimer's, Osteoarathritais, Ankylosing spondylitis

AstraZeneca/Pozen’s Vimovo combo drug cleared by US FDA, pushing US firm’s stock up 21%; AZ expands deal with Targacept

Article | 04 May 2010

Print This

USA-based Pozen saw its share price leap 21% to a 52-week high of $13.15 after, along with its partner, Anglo-Swedish drug major ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in